Baxter

Alexion adds Orloff, Law and Franchini to leadership team

Monday, June 5, 2017

Alexion Pharmaceuticals announced key additions to its executive leadership team. Reporting to Chief Executive Officer Ludwig Hantson will be: John Orloff, M.D., executive vice president, head of Research & Development; Anne-Marie Law, executive vice president, chief human resources officer; and Indrani Lall Franchini, J.D., executive vice president, chief compliance officer.

[Read More]

Alexion appoints Ludwig Hantson chief executive officer

Tuesday, March 28, 2017

Alexion Pharmaceuticals announced that its board of directors has appointed Ludwig N. Hantson, Ph.D., as chief executive officer and member of the board of directors, effective immediately. Dr. Hantson most recently served as president and CEO of Baxalta, a spin-off as a public company from Baxter, and a developer of therapies for orphan and underserved diseases in hematology, immunology and oncology. Dr. Hantson brings to Alexion a strong record of developing diverse rare disease pipelines and commercializing innovative and life-transformative therapies at industry-leading companies.

[Read More]

Syngene International commissions dedicated R&D center for Amgen

Thursday, September 8, 2016

Syngene International, one of Asia’s largest R&D-focused CROs, has announced the establishment in Bangalore, India, of an integrated, multi-disciplinary drug discovery and development center for Amgen. This center, named Syngene Amgen R&D Center (SARC), will be Syngene’s fourth such exclusive R&D center. Syngene already operates dedicated R&D centers for Bristol-Myers Squibb, Abbott Nutrition and Baxter.

[Read More]

Envigo appoints Scott Schulz Director of North American Operations

Thursday, May 26, 2016

Envigo has appointed Scott Schulz, MBA, to the post of director, North American (NA) Operations. In this role, Schulz will optimize operational performance and service delivery across the company’s North American based production locations for Research Models and Services (RMS). He will report directly to Michael Caulfield, president North American RMS at Envigo.

[Read More]

Baxalta launches focused on orphan diseases and underserved conditions

Thursday, July 2, 2015

Baxalta has launched as a global biopharmaceutical company dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions. The company continues to advance in hematology and immunology and seeks to expand its oncology portfolio for patients with limited treatment options. Baxalta plans to launch 20 new products by 2020, leveraging the company’s existing global capabilities and footprint in more than 100 countries.

[Read More]